The data is encouraging but early; monitor for initiation of the Phase 2 trial and any partnership or funding announcements. Given the small sample size and open-label design, the stock may react positively in the near term, but sustained upside depends on confirmatory data.
Price Chart
Executive Summary
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkinson's disease. Key positive findings include an 81% reduction in CSF GluSph in elevated-baseline patients and a 4.8-point difference in MDS-UPDRS scores favoring high-baseline patients at Day 150, with all 16 participants remaining on study. The data supports continued development toward a planned Phase 2 trial, but remains early-stage and open-label.
Key Facts
- GT-02287 showed an 81% reduction in CSF GluSph after 90 days in participants with elevated baseline levels.
- At Day 150, a 4.8-point difference in MDS-UPDRS Part II+III scores favored high-baseline GluSph participants over low-baseline.
- All 16 participants from Part 1 continued into the 9-month extension and remain on study through Day 150.
- Perceived benefits included improved smell/taste, balance/gait, and sleep in a subset of participants.
- A Phase 2 trial is planned with endpoints including UPSIT and wearable sensor gait assessments.
Financial Impact
No financial data provided; pre-revenue clinical-stage biotech.
Risk Factors
- Phase 1b open-label trial with small sample size (n=16) limits statistical reliability.
- Future Phase 2 trial may not replicate results; high failure rate in Parkinson's disease trials.
- Company is pre-revenue with $76M market cap; financing risk if cash runway is insufficient.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066062 |
| Document: 0001104659-26-066062-index-headers.html | 0001104659-26-066062 |
| Document: 0001104659-26-066062-index.html | 0001104659-26-066062 |
| Document: 0001104659-26-066062.txt | 0001104659-26-066062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.20 (−30.23%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.20 (−30.23%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.20 (−41.75%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.20 (−27.71%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.20 (−40.89%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.20 (−40.89%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.20 (−34.07%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.20 (−34.07%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.20 (−31.82%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.20 (−36.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers